OraSure Technologies (OSUR) Projected to Post Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR - Get Free Report) is projected to release its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $29.57 million for the quarter.

OraSure Technologies Trading Up 1.4 %

NASDAQ OSUR traded up $0.04 during trading hours on Friday, reaching $2.98. 231,554 shares of the company traded hands, compared to its average volume of 866,628. The stock has a market capitalization of $230.91 million, a PE ratio of 19.87 and a beta of 0.76. OraSure Technologies has a 12 month low of $2.69 and a 12 month high of $5.59. The company has a 50 day moving average of $3.22 and a two-hundred day moving average of $3.67.

OraSure Technologies declared that its board has approved a share buyback program on Monday, March 24th that permits the company to repurchase $40.00 million in shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 15.6% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its shares are undervalued.

Analysts Set New Price Targets

Separately, StockNews.com downgraded OraSure Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th.

Insider Activity

In other news, CEO Manner Carrie Eglinton purchased 78,625 shares of the stock in a transaction dated Thursday, February 27th. The stock was acquired at an average price of $3.15 per share, for a total transaction of $247,668.75. Following the completion of the transaction, the chief executive officer now owns 1,259,664 shares of the company's stock, valued at approximately $3,967,941.60. The trade was a 6.66 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John P. Kenny acquired 47,659 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was purchased at an average price of $3.17 per share, for a total transaction of $151,079.03. Following the completion of the transaction, the director now owns 70,915 shares in the company, valued at $224,800.55. The trade was a 204.93 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 190,284 shares of company stock valued at $600,348. Company insiders own 3.90% of the company's stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.